Caplin Steriles (Caplin), a Subsidiary Company of Caplin Point Laboratories, has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Desmopressin Acetate Injection USP, 4 mcg/mL single-dose vials and 40 mcg/10 mL (4 mcg/mL) multiple-dose vials, a generic therapeutic equivalent version of the Reference Listed Drug (RLD) DDAVP (desmopressin acetate) Injection, 4 mcg/mL of Nordic Pharma Inc., (NDA 018938). Desmopressin Acetate Injection is used to treat conditions like haemophilia A, von Willebrand disease, and central diabetes insipidus, helping to manage bleeding and regulate urine production. According to IQVIATM (IMS Health), Desmopressin Acetate injection USP, 4 mcg/mL single-dose vials and 40 mcg/10 mL (4 mcg/mL) multiple-dose vials had US sales of approximately $26 million for the 12-month period ending December 2025. Powered by Capital Market - Live News

Net profit of Caplin Point Laboratories rose 17.93% to Rs 163.88 crore in the quarter ended December 2025 as against Rs 138.96 crore during the previous quarter ended December 2024. Sales rose 10.10% to Rs 542.77 crore in the quarter ended December 2025 as against Rs 492.96 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales542.77492.96 10 OPM %34.9432.92 - PBDT223.17193.46 15 PBT203.89177.26 15 NP163.88138.96 18 Powered by Capital Market - Live News

Caplin Point Laboratories will hold a meeting of the Board of Directors of the Company on 5 February 2026.Powered by Capital Market - Live News

Net profit of Caplin Point Laboratories rose 18.08% to Rs 154.45 crore in the quarter ended September 2025 as against Rs 130.80 crore during the previous quarter ended September 2024. Sales rose 10.54% to Rs 534.04 crore in the quarter ended September 2025 as against Rs 483.10 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales534.04483.10 11 OPM %35.4234.08 - PBDT219.40185.22 18 PBT201.00168.46 19 NP154.45130.80 18 Powered by Capital Market - Live News

Net profit of Caplin Point Laboratories declined 2.98% to Rs 102.59 crore in the quarter ended September 2025 as against Rs 105.74 crore during the previous quarter ended September 2024. Sales declined 15.75% to Rs 175.18 crore in the quarter ended September 2025 as against Rs 207.93 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales175.18207.93 -16 OPM %43.3047.21 - PBDT135.02141.15 -4 PBT129.00134.66 -4 NP102.59105.74 -3 Powered by Capital Market - Live News